Navigation Links
ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
Date:1/8/2009

Patients treated at the initial dose in an ongoing Phase Ib trial demonstrated a 2.5 log10 median viral load decline after three days

Conference Call Today at 8:30AM EST

SAN DIEGO, Jan. 8 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced results from the first cohort of an ongoing Phase Ib clinical trial of ANA598, the Company's investigational non-nucleoside polymerase inhibitor. ANA598 was very well-tolerated and demonstrated potent antiviral activity in patients infected with chronic Hepatitis C virus (HCV) in this first cohort of the study.

Patients in the first cohort received 200 mg ANA598 (n=8) or placebo (n=2), twice-daily (bid) for three days. At the end of the treatment period, the median viral load decline was 2.5 log10 (>99%), with a range of 1.4-3.4 log10, for the eight patients who received ANA598. Three patients who received ANA598 were genotype 1a and demonstrated a median viral load decline of 1.6 log10, while five patients who received ANA598 were genotype 1b and demonstrated a median viral load decline of 2.6 log10. All eight patients who received ANA598 demonstrated a rapid decline in viral load, and no patients demonstrated viral rebound while on study drug. In addition to the robust viral load decline, ANA598 was very well-tolerated and there were no serious adverse events in the first dose cohort, although conclusions regarding longer-term safety and tolerability cannot be made until the results of future clinical trials of longer duration in more patients are known. Patients are currently being enrolled in the second cohort (400 mg bid) of the study. Anadys expects to report detailed data from multiple cohorts of the study at an upcoming medical conference.

"We are very pleased with the antiviral activity and safety of ANA598
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
8. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  Decision Resources ... specialties (medical oncology, hematology-oncology, rheumatology, gastroenterology, endocrinology and ... trials that a biosimilar has been assessed in ... product they choose to prescribe. ... report entitled Acceptance of Biosimilars Across ...
(Date:8/27/2014)... -- According to the new research ... Chairs, Dental Lasers), Current Trends, Opportunities - Global Forecast ... Market is expected to reach $7,138.9 million by ... a CAGR of 5.7% between 2014 and 2019. ... 61 figures spread through 167 pages and in-depth ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com announces ... in its catalogue: Global Heart Valve ... http://www.reportlinker.com/p02316644/Global-Heart-Valve-Repair-and-Replacement-Market-2014-2018.html About Heart Valve ... the human heart which control the flow of ... with heart valve diseases such as valvular stenosis, ...
Breaking Medicine Technology:Surveyed Physicians Expect to Choose Between Future Biosimilars Based on Robustness and Number of Clinical Trials 2Dental Equipment Market Worth $7,138.9 Million by 2019 2Dental Equipment Market Worth $7,138.9 Million by 2019 3Global Heart Valve Repair and Replacement Market 2014-2018 2Global Heart Valve Repair and Replacement Market 2014-2018 3Global Heart Valve Repair and Replacement Market 2014-2018 4
(Date:8/28/2014)... 2014 MMAR Medical is pleased to ... chance for regular customers to enjoy several perks and ... for a wholesale license. It’s a great choice for ... and others who regularly purchase medical braces but could ... your own active lifestyle or those of your club, ...
(Date:8/28/2014)... 28, 2014 On September 1st, the ... Back-to-School campaign. The goal is to help families ... calmly and effectively and without exposures to risky pesticides. ... agree: “Children’s exposures to pesticides should be limited ... , Head lice are often trivialized in the media, ...
(Date:8/27/2014)... Missouri (PRWEB) August 28, 2014 A ... Carey Danis & Lowe reports that the C.R. ... of thousands of consolidated transvaginal mesh lawsuits, recently filed ... PTO #136 pertains to the pretrial discovery process, and ... physically sensitive evidence. , Carey Danis & Lowe is ...
(Date:8/27/2014)... FL (PRWEB) August 27, 2014 ... money-saving dental plans, has launched in the state ... access to quality, affordable dental care services at ... destination for Tennessee consumers looking to save money ... dental rates as a member of discount fee ...
(Date:8/27/2014)... (PRWEB) August 28, 2014 For ... and XML websites, ASP.NET hosting products are very ... ), Arvixe, and FatCow are the best ASP.NET ... has been known as a top web hosting ... for reliability remains with it today. Recently proclaimed ...
Breaking Medicine News(10 mins):Health News:MMAR Medical Announces Customer Membership Program 2Health News:Head Lice Can Be a Public Health Opportunity 2Health News:Head Lice Can Be a Public Health Opportunity 3Health News:Head Lice Can Be a Public Health Opportunity 4Health News:Carey Danis & Lowe Reports On New Court Order in C.R. Bard Transvaginal Mesh MDL 2Health News:DentistSave.com Launches Discount Dental Plans in Tennessee for Consumers, Businesses, and Groups 2Health News:DentistSave.com Launches Discount Dental Plans in Tennessee for Consumers, Businesses, and Groups 3Health News:Top10BestSEOHosting.com Releases the Best ASP.NET Hosting Suppliers of This Year: Hostgator, Arvixe and FatCow 2
... and Medical Center, Phoenix, today announced the signing of ... for the deployment of the company,s state-of-the-art videoconferencing ... be used to connect specialist physicians at the hospital ... will include the Barrow Neurological Institute, as well as ...
... Essential survival gear for parents and guardians raising girls ... Changes (TM) is the leading product to help ... . (Photo: http://www.newscom.com/cgi-bin/prnh/20090512/LA13991 ) WHO: ... are Tara Harrington and Susanne Marcotte-Carroll, two ...
... percent lower in those who take supplements that long, research ... for at least a year before conception, folic acid supplements ... at least 50 percent, University of Texas researchers say. , ... PLoS Medicine , found no link to a reduction in ...
... who has developed a pioneering technique using microwaves to destroy ... UK and other patients are now being treated internationally. ... year die of primary liver cancer, with another million dying ... other tumour sites such as cancer of the colon. ...
... 2009) When Americans were asked to value the ... as they consider spending their own money, they chose ... revealed. , The Spectrum Health Value Study, the first ... representative sample of Americans over the past six months ...
... Human monoclonal antibodies effective against bird and seasonal ... colleagues, working with researchers at the Dana-Farber Cancer ... Prevention, reported the identification of human monoclonal antibodies ... viruses, including avian influenza A (H5N1) virus, previous ...
Cached Medicine News:Health News:St. Joseph's Hospital and Medical Center Signs Agreement for Innovative Video Conferencing Use 2Health News:Changes(TM) Kit for Girls - 'What Every Girl Wants.' 2Health News:Worldwide success in treatment of liver tumors 2Health News:Worldwide success in treatment of liver tumors 3Health News:Access to care leads Americans' priorities in first-ever public study of health value 2Health News:Recent developments at Burnham Institute for Medical Research, May 2009 2Health News:Recent developments at Burnham Institute for Medical Research, May 2009 3Health News:Recent developments at Burnham Institute for Medical Research, May 2009 4Health News:Recent developments at Burnham Institute for Medical Research, May 2009 5
... mm applier contains 20 titanium clips in the ... in the L size. The appliers are designed ... Auto Suture trocar sleeves, or larger sized trocar ... introduction of the ENDO CLIP clip applier through ...
... The Tissue Lock Clip is designed with ... superior on-vessel clip retention and improved hemostasis., ... design has a 20 percent greater angle ... placement., ,The Reflex® ELC has an ...
Insert only, Pilling-Weck small clip size...
Insert only, Ethicon, medium clip size...
Medicine Products: